|
BIIB's Revenue Growth by Quarter and Year
Biogen Inc 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BIIB Revenue (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
2,544.00
|
2,733.80
|
2,852.60
|
| III Quarter |
September |
-
|
2,508.50
|
2,778.90
|
3,376.10
|
| II Quarter |
June |
2,456.00
|
2,589.10
|
2,775.00
|
3,681.60
|
| I Quarter |
March |
2,463.00
|
2,531.80
|
2,694.00
|
3,534.30
|
| FY |
|
4,919.00
|
10,173.40
|
10,981.70
|
13,444.60
|
| BIIB Revenue second quarter 2023 Y/Y Growth Comment |
Biogen Inc reported decrease in Revenue in the second quarter 2023 by -5.14% to $ 2,456.00 millions, from the same quarter in 2022.
The decrease in the second quarter 2023 Biogen Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 10.54%.
Looking into second quarter 2023 results within Biotechnology & Pharmaceuticals industry 45 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue decline of -5.14% ranks overall at the positon no. 2637 in the second quarter 2023.
|
| BIIB Revenue ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-6.94 % |
-4.16 % |
-22.3 % |
| III Quarter |
September |
- |
-9.73 % |
-17.69 % |
-6.22 % |
| II Quarter |
June |
-5.14 % |
-6.7 % |
-24.63 % |
1.79 % |
| I Quarter |
March |
-2.72 % |
-6.02 % |
-23.78 % |
1.28 % |
| FY |
|
- |
-7.36 % |
-18.32 % |
-6.49 % |
BIIB Revenue (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
1.42 % |
-1.62 % |
-15.51 % |
| III Quarter |
September |
- |
-3.11 % |
0.14 % |
-8.3 % |
| II Quarter |
June |
-0.28 % |
2.26 % |
3.01 % |
4.17 % |
| I Quarter |
March |
-3.18 % |
-7.39 % |
-5.56 % |
-3.73 % |
| FY (Year on Year) |
|
- |
-7.36 % |
-18.32 % |
-6.49 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 96.03 % |
10.54 % |
-24.63 % |
| (Dec. 31, 2004) |
|
(Jun 30 2021) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 96.03 % |
10.54 % |
-24.63 % |
| (Dec. 31, 2004) |
|
(Jun 30 2021) |
|
| Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Biogen Inc 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.14 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's II. Quarter Q/Q Revenue Comment |
In the II. Quarter 2023 Biogen Inc reported decrease in Revenue from the previous quarter by -0.28% to $ 2,456.00 millions, from $ 2,463.00 millions achived in the previous reporting period.
Albeit periodic factors usually elevate II. Quarter 2023 performance, this simply could not be substantial to salvage BIIB's outcome, George Wood, Healthcare sector advisor said and continued that average sequential Revenue growth is at 3.14% for Biogen Inc .
Within Biotechnology & Pharmaceuticals industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2510. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.14 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's II. Quarter Q/Q Revenue Comment |
In the II. Quarter 2023 Biogen Inc disclosed decrease in Revenue from the first quarter by -0.28% to $ 2,456.00 millions, from $ 2,463.00 millions released in the previous reporting period.
Even seasonal factors which usually energize II. Quarter 2023 Revenue, this simply has not been sufficient to salvage BIIB's II. Quarter outcome, George Wood, Healthcare sector advisor pointed out.
Within Biotechnology & Pharmaceuticals industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2510. |
|
Biogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
| Cumulative Revenue 12 Months Ending |
$ 9,971.50 |
$ 10,104.60 |
$ 10,173.40 |
$ 10,363.20 |
$ 10,633.60 |
| Y / Y Revenue Growth (TTM) |
-6.23 % |
-6.61 % |
-7.36 % |
-6.64 % |
-9.1 % |
| Year on Year Revenue Growth Overall
Ranking |
# 141 |
# 152 |
# 2214 |
# 2747 |
# 87 |
| Seqeuential Revenue Change (TTM) |
-1.32 % |
-0.68 % |
-1.83 % |
-2.54 % |
-1.72 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 125 |
# 2665 |
# 1882 |
# 2879 |
# 90 |
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Biogen Inc 's annual Revenue decline would be -6.23% year on year to $9,972 millions.
Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 141, from total ranking in previous quarter at 152. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
41.42 % |
9.68 % |
-22.17 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
9.68 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 6 |
| S&P 500 |
# 125 |
|
| Cumulative Revenue growth
Comment |
Biogen Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Biogen Inc 's annual Revenue fall would be -6.23% year on year to $9,972 millions.
Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 141, from total ranking in previous quarter at 152. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
41.42 % |
9.68 % |
-22.17 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
9.68 % |
-22.17 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 6 |
| S&P 500 |
# 125 |
|
